Skip to main content

Table 3 Protein expression and genetic mutation by intrinsic subtypes

From: The relevance of the intrinsic subtype to the clinicopathological features and biomarkers in Japanese breast cancer patients

  All cases ER/PR + HER2- ER/PR + HER2+ HER2 type Basal-like Unclassified P
Cases (%) 471 (100) 306 (65.0) 41 (8.7) 59 (12.5) 37 (7.9) 28 (5.9)  
EGFR   <0.01
Positive 74 (16.0) 16 (5.4) 5 (12.5) 19 (32.8) 34 (91.9) 0 (0)
Negative 388 (84.0) 283 (94.6) 35 (87.5) 39 (67.2) 3 (8.1) 28(100)
Missing 9 7 1 1   
PTEN   <0.01
Reduced 234 (50.9) 156 (52.7) 18 (43.9) 16 (27.6) 28 (75.7) 16 (57.1)
Normal 226 (49.1) 140 (47.3) 23 (56.1) 42 (72.4) 9 (24.3) 12 (42.9)
Missing 11 10   1   
IGF- 1R 0.77
Positive 397 (85.9) 255 (85.6) 36 (87.8) 50 (86.2) 30 (81.1) 26 (92.9)
Negative 65 (14.1) 43 (14.4) 5 (12.2) 8 (13.8) 7 (18.9) 2 (7.1)
Missing 9 8   1   
Bcl- 2 <0.01
Positive 303 (65.0) 249 (83.0) 27 (67.5) 7 (12.1) 6 (16.2) 14 (50.0)
Negative 160 (35.0) 51 (17.0) 13 (32.5) 51 (87.9) 31 (83.8) 14 (50.0)
Missing 8 6 1 1   
c- Kit <0.01
Positive 33 (7.1) 15 (5.0) 0 (0) 7 (12.1) 10 (27.0) 1 (3.6)
Negative 433 (92.9) 287 (95.0) 41 (100) 51 (87.9) 27 (73.0) 27 (96.4)
Missing 5 4   1   
c- Met 0.03
Positive 328 (72.6) 203 (69.5) 34 (82.9) 47 (85.5) 28 (75.7) 16 (59.3)
Negative 124 (27.4) 89 (30.5) 7 (17.1) 8 (14.5) 9 (24.3) 11 (40.7)
Missing 19 15   4   1
HIF- 0.76
Positive 159 (34.1) 110 (36.4) 12 (29.3) 18 (31.0) 11 (29.7) 8 (28.6)
Negative 307 (65.9) 192 (63.6) 29 (70.7) 40 (69.0) 26 (70.2) 20 (71.4)
Missing 5 4     
PDGFRA 0.49
Positive 393 (86.9) 255 (87.6) 34 (85.0) 52 (91.2) 30 (81.1) 22 (81.5)
Negative 59 (13.1) 36 (12.4) 6 (15.0) 5 (8.8) 7 (18.9) 5 (18.5)
Missing 19 15 1 2   1
Survivin 0.02
Positive 383 (82.4) 240 (79.5) 34 (85.0) 56 (96.6) 30 (81.1) 23 (82.1)
Negative 82 (17.6) 62 (20.5) 6 (15.0) 2 (3.4) 7 (18.9) 5 (18.9)
Missing 6 4 1 1   
VEGFR2 0.59
Positive 318 (68.1) 206 (68.0) 25 (61.0) 44 (75.9) 25 (67.6) 18 (64.3)
Negative 149 (31.9) 97 (32.0) 16 (39.0) 14 (24.1) 12 (32.4) 10 (35.7)
Missing 4 3   1   
VEGF- A 0.14
Positive 279 (60.4) 180 (60.0) 25 (61.0) 42 (72.4) 18 (48.6) 14 (50.0)
Negative 183 (39.6) 118 (40.0) 16 (39.0) 16 (27.6) 19 (51.4) 14 (50.0)
Missing 9 8   1   
PIK3CA exon 9 0.94
Mutated 8 (8.8) 6 (9.7) 0 (0) 1 (10.0) 0 (0) 1 (14.3)
Wild type 83 (91.2) 56 (90.3) 6 (100) 9 (90.0) 6 (100) 6 (85.7)
Missing 380 45 35 49 31 22
PIK3CA exon 20 0.17
Mutated 28 (7.8) 20 (8.7) 4 (14.3) 1 (2.2) 3 (10.3) 0 (0)
Wild type 329 (92.2) 211 (91.3) 24 (85.7) 44 (97.8) 26 (89.7) 24 (100)
Missing 114 75 13 14 8 4
  1. EGFR: epidermal growth factor receptor, PTEN: phosphatase and tensin homolog deleted on chromosome 10, IGF-1R: insulin-like growth factor-1 receptor, Bcl-2: B-cell lymphoma 2, c-Met: hepatocyte growth factor receptor, HIF-1α: hypoxia-inducible factor 1-alpha, PDGFRA: alpha-type platelet-derived growth factor receptor, VEGFR2: vascular endothelial growth factor receptor 2, VEGF-A: vascular endothelial growth factor A.